Gilead Sciences (NASDAQ: GILD) has enjoyed remarkable success in the past year thanks to the launch of two instant billion-dollar blockbuster hepatitis C therapies, however, even best-in-breed biotech stocks like Gilead Sciences still face risks that could leave investors in the lurch. Read on to learn which three risks concern me most, and how they could impact Gilead Sciences down […]
Source: Gilead Sciences.Gilead Sciences surprised investors when it recently announced that it will begin returning some of its cash stockpile to investors in the form of a dividend. Since dividend-paying biotech stocks are a bit of a rarity, we asked two Motley Fool healthcare experts for their opinion on whether Gilead Sciences’ dividend plan makes sense. Read on to learn […]
Source: Flickr user stockmonkeys.com .The pop-and-drop nature of the biotech industry makes owning stocks in the sector particularly dicey. But for investors willing to take on the risk of failure, a number of intriguing small-cap biotech companies are working on important new therapies that could make a big impact on patients’ lives and investors’ wallets. Here are three of thesecompanies.No. […]
Judging from the atmosphere at last week’s JP Morgan Healthcare conference in San Francisco – which industry veteran and long-time participant Henri Termeer described as the “most optimistic” he had every experienced – the industry’s well-documented problems are clearly behind us. After a decade in the doldrums, the biotech market is on a bull run stretching back more than a […]
Michael A. RobinsonToday I want to reintroduce you to a biotech stock that Wall Street has been pricing as though it were dead money.This biotech company recently filed a stellar earnings report. But those earnings were slightly off analyst expectations, and the share price dipped – making this is yet another stock that sells off after a slight miss, a […]
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and rough trading in between. Encouraging industry trends, increasing merger and acquisition activities, expansion into emerging markets and ever-increasing health care spending led the sector to easily outperform the broader U.S. equity markets.Though lofty valuations and regulatory concerns did bring in some pain […]
Indexes were up most of the session as a surge by Apple (AAPL) helped lift things; this is a massive component of the NASDAQ. The S&P 500 gained 0.18% and the NASDAQ 0.40%. It was a very busy day with a lot of blockbuster companies reporting so we’ll focus on that today.Here are the longer term charts for the 2 […]
